| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.08 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.08 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.08 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.096 | 0.08 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.093 | 0.08 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.094 | 0.09 |